Critical brain injuries requiring drainage tubes could soon be monitored continuously rather than through periodic laboratory tests, potentially catching life-threatening infections hours or days earlier. Current intensive care protocols depend on manually collecting spinal fluid samples every few hours, creating dangerous gaps where complications can develop undetected.
The NeuroSense platform integrates directly into existing brain drainage systems, simultaneously tracking glucose levels, lactate concentrations, pH balance, and fluid flow rates through specialized biosensors. The glucose and lactate sensors use aptamer-based electrochemical detection, while pH monitoring employs polydopamine chemistry and flow measurement relies on impedance changes. Clinical validation in ICU patients showed strong agreement with standard laboratory reference methods, while maintaining sensor stability in human cerebrospinal fluid for multiple days.
This technology addresses a critical blind spot in neurocritical care where infections like ventriculitis can rapidly progress between routine samplings. Early detection of metabolic shifts—such as rising lactate or falling glucose—could trigger immediate antibiotic intervention before systemic complications develop. The continuous flow monitoring also provides instant alerts for catheter blockages or positioning problems that compromise drainage effectiveness.
While promising, the platform requires extensive validation across diverse patient populations and longer monitoring periods. The integration of multiple sensor types into a single sterile system represents significant engineering complexity. However, if successful in larger trials, this approach could transform neurocritical care by shifting from reactive to predictive monitoring, potentially reducing both complications and length of intensive care stays for vulnerable brain injury patients.